1. Report Introduction 2. Systemic Juvenile Idiopathic Arthritis (SJIA) Market Overview at a Glance 2.1. Market Share Distribution of Systemic Juvenile Idiopathic Arthritis (SJIA) in 2016 2.2. Market Share Distribution of Systemic Juvenile Idiopathic Arthritis (SJIA) in 2028 3. Disease Background and Overview: Systemic Juvenile Idiopathic Arthritis (SJIA) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Systemic Juvenile Idiopathic Arthritis (SJIA) in 7MM 4.3. Total Prevalent Patient Population of Systemic Juvenile Idiopathic Arthritis (SJIA) in 7MM – By Countries 5. Epidemiology of Systemic Juvenile Idiopathic Arthritis (SJIA) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.1.3. Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.1.4. Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.1.5. Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.1.6. Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.4.3. Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.4.4. Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.4.5. Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.4.6. Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.5.3. Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.5.4. Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.5.5. Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.5.6. Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.6.3. Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.6.4. Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.6.5. Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.6.6. Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.7.3. Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.7.4. Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.7.5. Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.7.6. Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.8.3. Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.8.4. Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.8.5. Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.8.6. Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.9.3. Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.9.4. Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) * 5.9.5. Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 5.9.6. Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Systemic Juvenile Idiopathic Arthritis (SJIA) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Systemic Juvenile Idiopathic Arthritis (SJIA) : 7MM Market Analysis 12.1. 7MM Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) 12.2. 7MM Percentage Share of drugs marketed for Systemic Juvenile Idiopathic Arthritis (SJIA) 12.3. 7MM Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Products 13. Systemic Juvenile Idiopathic Arthritis (SJIA) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in United States 13.1.2. Percentage Share of drugs marketed for Systemic Juvenile Idiopathic Arthritis (SJIA) in United States 13.1.3. Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany 13.2.1.2. Percentage Share of drugs marketed for Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany 13.2.1.3. Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in France 13.2.2.2. Percentage Share of drugs marketed for Systemic Juvenile Idiopathic Arthritis (SJIA) in France 13.2.2.3. Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy 13.2.3.2. Percentage Share of drugs marketed for Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy 13.2.3.3. Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain 13.2.4.2. Percentage Share of drugs marketed for Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain 13.2.4.3. Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Systemic Juvenile Idiopathic Arthritis (SJIA) in United Kingdom 13.2.5.3. Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan 13.3.2. Percentage Share of drugs marketed for Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan 13.3.3. Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in 7MM Table 2: Total Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Table 5: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Table 6: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Table 7: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Table 11: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Table 12: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Table 14: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Table 15: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Table 16: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Table 17: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Table 21: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Table 22: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Table 26: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Table 27: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Table 30: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Table 31: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Table 32: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Table 36: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Table 37: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Table 42:7MM- Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Table 45: United States-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Table 48: Germany-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Table 51: France-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Table 54: Italy-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Table 57: Spain-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Table 60:UK-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Table 63: Japan-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in 7MM Figure 2: Total Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Figure 6: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Figure 7: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Figure 12: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Figure 15: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Figure 16: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Figure 17: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Figure 22: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Figure 27: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Figure 31: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Figure 32: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Figure 37: Treatable Cases of the Systemic Juvenile Idiopathic Arthritis (SJIA) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Figure 42:7MM- Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Figure 45: United States-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Figure 48: Germany-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Figure 51: France-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Figure 54: Italy-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Figure 57: Spain-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Figure 60:UK-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Systemic Juvenile Idiopathic Arthritis (SJIA) in USD MM (2016-2028) Figure 63: Japan-Market Share Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Systemic Juvenile Idiopathic Arthritis (SJIA) by Therapies in USD MM (2016-2028)